for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Acceleron Pharma Inc

XLRN.OQ

Latest Trade

43.10USD

Change

-0.19(-0.44%)

Volume

290,080

Today's Range

42.69

 - 

43.44

52 Week Range

37.01

 - 

59.54

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
43.29
Open
43.24
Volume
290,080
3M AVG Volume
5.99
Today's High
43.44
Today's Low
42.69
52 Week High
59.54
52 Week Low
37.01
Shares Out (MIL)
52.83
Market Cap (MIL)
2,287.17
Forward P/E
-18.87
Dividend (Yield %)
--

Next Event

Q3 2019 Acceleron Pharma Inc Earnings Release

Latest Developments

More

Acceleron To Discontinue Development Of Ace-083 In Facioscapulohumeral Muscular Dystrophy

Acceleron Receives FDA Orphan Drug Designation For Sotatercept

Acceleron Qtrly Loss Per Share $0.34

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Acceleron Pharma Inc

Acceleron Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily. It has four internally discovered therapeutic candidates that are in clinical trials, which include luspatercept, sotatercept, dalantercept and ACE-083. It offers a platform technology, IntelliTrap. It is also evaluating ACE-1332, a selective TGF-beta antagonist, for treatment of disorders with a fibrotic component, and additional molecules from its IntelliTrap platform for undisclosed therapeutic areas. Dalantercept is designed to treat cancers by inhibiting blood vessel formation by inhibiting signaling through the ALK1 receptor. ACE-083 is designed to promote muscle growth and function in specific, targeted muscles.

Industry

Biotechnology & Drugs

Contact Info

128 Sidney St

+1.617.6499200

http://www.acceleronpharma.com/

Executive Leadership

Francois E. Nader

Independent Chairman of the Board

Habib J. Dable

President, Chief Executive Officer, Director

Kevin F. McLaughlin

Chief Financial Officer, Senior Vice President, Treasurer

John D. Quisel

Executive Vice President, Chief Business Officer, Secretary

Ravindra Kumar

Senior Vice President, Chief Scientific Officer

Key Stats

2.00 mean rating - 12 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.1K
EPS (USD)

2016

-1.520

2017

-2.680

2018

-2.590

2019(E)

-2.276
Price To Earnings (TTM)
--
Price To Sales (TTM)
60.96
Price To Book (MRQ)
4.57
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-27.76
Return on Equity (TTM)
-26.51

Latest News

BRIEF-Acceleron Begins Phase 2 Trial Of Pulmonary Arterial Hypertension Treatment

* ACCELERON ANNOUNCES INITIATION OF PULSAR PHASE 2 TRIAL OF SOTATERCEPT IN PULMONARY ARTERIAL HYPERTENSION

BRIEF-Acceleron Reports Q1 Loss Per Share $0.58

* ACCELERON REPORTS FIRST QUARTER 2018 OPERATING AND FINANCIAL RESULTS

BRIEF-Acceleron Receives FDA Fast Track Designation For Ace-083 In Facioscapulohumeral Muscular Dystrophy

* ACCELERON RECEIVES FDA FAST TRACK DESIGNATION FOR ACE-083 IN FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD) Source text for Eikon: Further company coverage:

BRIEF-Acceleron Pharma Q4 Loss Per Share $‍0.62​

* ACCELERON REPORTS FOURTH QUARTER AND FULL YEAR 2017 OPERATING AND FINANCIAL RESULTS

BRIEF-Acceleron plans to initiate part 2 of ACE-083 FSHD phase 2 trial during Q2 of 2018

* ACCELERON PHARMA INC - PLANS TO INITIATE PART 2 OF ACE-083 FSHD PHASE 2 TRIAL DURING Q2 OF 2018

BRIEF-BioAg Alliance Announces Updated Research And Development Pipeline

* BIOAG ALLIANCE - ANNOUNCED UPDATED RESEARCH AND DEVELOPMENT PIPELINE

BRIEF-Acceleron ‍expects to initiate a phase 2 trial in 1H 2018​

* Acceleron announces preclinical results in pulmonary arterial hypertension at the American Heart Association 2017 Scientific Sessions

BRIEF-Acceleron Pharma qtrly net loss per share $0.65

* Acceleron Pharma reports third quarter 2017 operational and financial results

BRIEF-Acceleron announces pricing of public offering of common stock

* Acceleron announces pricing of public offering of common stock

BRIEF-Acceleron announces proposed public offering of common stock

* Acceleron announces proposed public offering of common stock

BRIEF-Acceleron Pharma Q2 loss per share $0.77

* Acceleron Pharma reports second quarter 2017 operational and financial results

BRIEF-Acceleron announces first patient treated in phase 2 clinical trial of ACE-083

* Acceleron announces first patient treated in phase 2 clinical trial of ACE-083 in Charcot-Marie-Tooth disease Source text for Eikon: Further company coverage:

BRIEF-Acceleron announces top-line results from dart phase 2 study of dalantercept

* Acceleron announces top-line results from dart phase 2 study of dalantercept in advanced renal cell carcinoma

BRIEF-Celgene and Acceleron complete enrollment in MEDALIST, BELIEVE Phase 3 studies of luspatercept

* Celgene and Acceleron complete target enrollment in the medalist and believe Phase 3 studies of luspatercept in myelodysplastic syndromes and beta-thalassemia

BRIEF-Acceleron Pharma qtrly loss per share $0.66

* Acceleron pharma reports first quarter 2017 operational and financial results

BRIEF-Acceleron announces management change

* Acceleron Pharma Inc - Steven Ertel, due to medical reasons, will transition from his role as executive vice president and chief operating officer

BRIEF-Acceleron says enrolment for late stage studies now expected to be completed in Q2

* Acceleron provides clinical development updates on luspatercept program

BRIEF-Acceleron to initiate phase 2 trial of ACE-083 in charcot-marie-tooth neuromuscular disease

* Acceleron announces plans to initiate a phase 2 trial of ACE-083 in charcot-marie-tooth neuromuscular disease and host educational webinar

BRIEF-Acceleron outlines corporate goals and priorities for 2017

* Plan to initiate new luspatercept phase 2 clinical trials in distinct patient segments in MDS and Beta-Thalassemia

BRIEF-Acceleron Pharma reports Q3 financial and operational results

* Acceleron Pharma reports third quarter 2016 financial and operational results Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up